Cancer studies

2020

  • A clear increase in TILs and modest tumor growth inhibition by pembrolizumab in prostate cancer tumors growing in bone of CD34+ engrafted NOG mice at SITC 2020 Annual Meeting by Mari Suominen
  • Differential Effects of Two Immunomodulators, Chemotherapy and Bone
    targeting Agent on Cancer Progression in a Syngeneic Bone Metastasis Model of Triple Negative Breast Cancer presented at Advances of Immuno-Oncology Congress 2020 by Mari Suominen
  • T Cell Killing Assay for Analyzing the Effects of Immunotherapies In Vitro presented at Advances in Immuno-Oncology Congress 2020 by Jenni Mäki-Jouppila
  • Efficacy of anti-PD-1, IDO inhibitor, chemotherapy and bone-targeting agent on tumor growth in a syngeneic bone metastasis model of triple-negative breast cancer presented at AACR Annual Meeting 2020 by Mari Suominen
  • Immune cell killing assay for analyzing the effects of immunomodulating agents in vitro presented at AACR Annual Meeting 2020 by Jenni Mäki-Jouppila
  • Orthotopic and bone metastasis prostate cancer models using the 22Rv1 cell line presented at AACR Annual Meeting 2020 by Justyna Zdrojewska
  • Efficacy of Pembrolizumab and Assessment of Tumor-Infiltrating Immune Cells in Preclinical Models of Primary and Bone Metastatic Triple-Negative Breast Cancer at Tumor Models San Francisco meeting by Mari Suominen
  • Characterization of Anti-CTLA-4 Effects on Tumor Growth and Immune Microenvironment in a Syngeneic CT26.WT Colon Carcinoma Mouse Model at Tumor Models San Francisco meeting by Justyna Zdrojewska

2019

  • Pitfalls in preclinical development of immunotherapies for ER+ breast cancer: estrogen as an immunomodulator potentially influencing pembrolizumab efficacy in a breast cancer model in humanized mice in collaboration with Univeristy Central Animal Laboratory (University of Turku) and Taconic BioSciences presented at the SITC 2019 Meeting
  • Lack of immunotherapy efficacy in a syngeneic bone metastasis model of triple-negative breast cancer presented at the AACR-NCI-EORTC Meeting in 2019
  • Establishment of a novel prostate cancer bone metastasis model in humanized mice and early efficacy results of pembrolizumab in collaboration with Taconic Biosciences presented at the AACR-NCI-EORTC Meeting in 2019
  • Establishment of primary tumor models of TNBC and ER+/HER2- breast cancer in humanized mice and validation of pembrolizumab efficacy in collaboration with Taconic Biosciences presented at the AACR-NCI-EORTC Meeting in 2019
  • Validation of a preclinical model for bone metastatic triple negative breast cancer in collaboration with Polyphor Ltd presented at the AACR Annual Meeting in 2019
  • In vitro osteoblast assays for studying the effects of cancer therapeutics on bone biology presented at the AACR Annual Meeting in 2019
  • Systemic and local syngeneic bone metastasis models for immuno-oncology drug development in collaboration with Bayer AG presented at the AACR Annual Meeting in 2019
  • Characterization of anti-CTLA-4 effects on tumor growth and immune microenvironment in a syngeneic CT26.WT colon carcinoma mouse model in collaboration with OracleBio and BioSiteHisto presented at the AACR Annual Meeting in 2019
  • Establishment of a HER2 positive breast cancer bone metastasis model for validation of novel therapies in collaboration with Bayer AS presented at the AACR Annual Meeting in 2019
  • Establishment of a metastatic orthotopic model of pancreatic ductal adenocarcinoma (PDAC) for drug development in collaboration with Pharmaxis presented at the AACR Annual Meeting in 2019
  • The relevance of using proper preclinical models when developing therapeutics for localized or bone metastatic prostate cancer presented at the AACR Annual Meeting in 2019

2018

  • Systemic and local syngeneic bone metastasis models for immuno-oncology drug development in collaboration with Bayer AG presented at the EORTC-NCI-AACR Symposium in 2018
  • Characterization of tumor-infiltrating immune cells and the efficacy of pembrolizumab in preclinical models of primary and bone metastatic triple-negative breast cancer in collaboration with Taconic Biosciences and BioSiteHisto Ltd presented at the EORTC-NCI-AACR Symposium in 2018
  • Prostate Cancer Bone Metastasis Model for Preclinical Evaluation of Radiotherapeutics presented at EANM’ 18 Congress (E-poster walk)
  • Characterization of pre-clinical models of luminal B breast cancer in orthotopicand bone metastatic settings in collaboration with BioSiteHisto Ltd presented at the 15th European Pathology Congress 2018
  • Characterization of Tumor Growth Supported by Novel Dihydrotestosterone Releasing Implants in a Subcutaneous Prostate Cancer Xenograft Model in collaboration with PreclinApps Ltd presented at the Scand-LAS 2018 Annual Meeting

  • PD-1/PD-L1 Expression and Tumor-Infiltrating Immune Cells in Triple-Negative Breast Cancer: Characterization of Preclinical Primary Tumor and Bone Metastasis Models in Humanized Mice in collaboration with Taconic Biosciences and BioSiteHisto Ltd presented at the AACR Annual Meeting in 2018
  • Hormone Receptor and HER2/HER3 Expression in Preclinical Breast Cancer Models of Primary Tumor and Bone Metastasis in collaboration with Taconic Biosciences and BioSiteHisto Ltd presented at the AACR Annual Meeting in 2018
  • Drug Sensitivity Profiling of BT-474 Breast Cancer Cell Line for Identification of Novel Therapies Targeting HER2-positive Breast Cancer in collaboration with Institute for Molecular Medicine Finland FIMM presented at the AACR Annual Meeting 2018
  • Phenotypic Screening Using AMIDA Identifies Different Drug Responses in Breast and Prostate Cancer Cell Lines in an Organotypic Cell Culture Model in collaboration with University of Turku presented at the AACR Annual Meeting in 2018
  • Differential Efficacy of PD-1 Targeted Immunomodulation in Preclinical Models of Primary and Bone Metastatic Triple-Negative Breast Cancer in collaboration with BioSiteHisto Ltd and Taconic Biosciences presented at the AACR Annual Meeting in 2018
  • Castration-Resistant Prostate Cancer Bone Metastasis Model to Assess New Therapeutics in collaboration with Bayer AG presented at the AACR Annual Meeting in 2018
  • Anti-PD-1 Therapy Reduces Bone Lesion Growth in a Novel Syngeneic Bladder Cancer Bone Metastasis Model in collaboration with Bayer AG presented at the AACR Annual Meeting in 2018
  • Humanized Mouse Models of Triple-Negative and Triple-Positive Breast Cancer for Preclinical Validation of Novel Immuno-Oncology Therapies in collaboration with BioSiteHisto Ltd and Taconic Biosciences presented at the ITOC5 Conference in 2018

2017

  • Bone phenotype of human immune system engrafted mice in collaboration with Taconic Biosciences at the ASBMR Annual Meeting in 2017
  • Effects of estrogen removal by ovariectomy on growth of human MCF-7 breast cancer cells in bone at the ASBMR Annual Meeting in 2017
  • Active human immune system induces more severe osteoblastic bone reaction in a humanized mouse model of breast cancer bone metastasis in collaboration with Taconic Biosciences at ASBMR Annual Meeting 2017 (oral presentation)
  • Preclinical efficacy model to promote immunotherapy development for prostate cancer at AACR Annual Meeting in 2017
  • New preclinical model for immuno-oncology: Combination of tumor, bone microenvironment and immune system in collaboration with Taconic Biosciences at AACR Annual Meeting in 2017
  • Immunodeficient mice differentially sensitize to estrogen and exhibit severe estrogen-related adverse effects in orthotopic breast cancer model in collaboration with Taconic Biosciences at AACR Annual Meeting in 2017
  • Drug sensitivity profile of 5TGM1 murine multiple myeloma cell line emphasizes the translational potential of the syngeneic in vivo model in collaboration with Institute for Molecular Medicine Finland FIMM at AACR Annual Meeting in 2017
  • Selective drug sensitivity score (DSS) for indolent and aggressive prostate cancer cell lines in collaboration with Institute for Molecular Medicine Finland FIMM at AACR Annual Meeting in 2017
  • Importance of Tumor Microenvironment in the Preclinical Estrogen Receptor Positive Breast Cancer –Primary Tumor and Bone Metastasis Models with Orion Corporation Orion Pharma at AACR Annual Meeting in 2017 (Oral Presentation)
  • Additive benefits of radium-223 dichloride and bortezomib combination in a syngeneic 5TGM1 multiple myeloma mouse model with Bayer Healthcare at AACR Annual Meeting in 2017
  • Estrogen induces severe urinary tract defects –a strain dependent difference in nude vs NOG female mice with Taconic Biosciences at Scand-LAS 2017 (oral presentation)

2016

  • Differential drug sensitivity score (DSS) for indolent and aggressive prostate cancer cell lines with Fimm at EORTC-NCI-AACR Meeting in 2016
  • Effects of cabozantinib alone and in combination with bortezomib in the 5TGM1 murine multiple myeloma model with Exelixis at ASBMR Annual Meeting in 2016
  • New models of breast and lung cancer bone metastases for preclinical efficacy testing with Bayer Healthcare at AACR Annual Meeting in 2016
  • PI3K inhibitor BAY 1082439 and radium-223 dichloride decrease tumor burden and tumor-induced bone formation in an established bone metastastatic prostate cancer model in mice with Bayer Healthcare at AACR Annual Meeting in 2016
  • Establishment of realistic patient-derived preclinical models for prostate cancer bone metastasis at AACR Annual Meeting in 2016
  • Utilizing a novel luciferase labeling technique to establish and validate preclinical models of pancreatic cancer at AACR Annual Meeting in 2016
  • Effects of cabozantinib alone and in combination with bortezomib in the 5TGM1 murine multiple myeloma model with Exelixis Inc. and PreclinApps Ltd. at ASBMR Annual Meeting in 2016

2015

  • Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumor and tumor-induced bone growth in two osteoblastic prostate cancer models with Bayer Healthcare at AACR Annual Meeting in 2015
  • Effects of combination treatment with cabozantinib and bortezomib in the 5TGM1 murine multiple myeloma model with Exelixis at AACR Annual Meeting in 2015 (multiple myeloma)
  • Novel luciferase labeling technique to improve imaging of orthotopic pancreatic cancer model at AACR Annual Meeting in 2015
  • Establishment of realistic patient-derived preclinical models for prostate cancer bone metastasis at Hanson Wade Tumor Models Boston in 2015

2014

  • Radium-223 dichloride – Efficacy and mode-of-action in a mouse model of prostate cancer bone metastasis with Bayer Healthcare at EORTC-NCI-AACR Symposium 2014 (radiotherapeutics and metastasis)
  • Combination of PI3K inhibitor BAY 1082439 with radium-223 is a promising treatment of cancer with bone metastases with Bayer Healthcare at AACR Annual Meeting in 2014 (radiotherapeutics and bone metastasis)
  • A new spectrum-selective cathepsininhibitor, VBY-825, inhibits bone destruction in a syngeneic 5TGM1 multiple myeloma mouse model with Virobay at AACR Annual Meeting in 2014 (multiple myeloma)
  • Effects of Cabozantinib in the 5TGM1 murine multiple myeloma model with Exelixis at AACR Annual Meeting in 2014 (multiple myeloma)
  • Culturing Cancer Cells on Myoma Tissue: Development of a Novel Fully Human Organotypic 3D Invasion Model Applicable as a Preclinical Tool for Cancer Drug Development with University of Oulu and Oulu University Hospital at World Pharma Congress in 2014
  • Development and validation of clinically predictive models for anti-cancer drug development at International Conference on Drug Discovery and Therapy in 2014

2013

  • Radium-223 dichloride monotherapy and combination therapy with zoledronic acid or doxorubicin improve survival in a mouse model of breast cancer bone metastasis with Bayer HealthCare at CIBD Annual Meeting in 2013
  • A new spectrum-selective cathepsin inhibitor, VBY-825, inhibits bone destruction in a syngeneic 5TGM1 multiple myeloma mouse model with Virobay at CIBD Annual Meeting in 2013
  • Radium-223 dichloride monotherapy and combination therapy with zoledronic acid or doxorubicin improve survival in a mouse model of breast cancer bone metastasis with Bayer HealthCare at AACR Annual Meeting in 2013
  • Inhibiting androgen receptor-associated Src signaling with VAL201 inhibits breast cancer growth in an orthotopic xenograft model with Valirx at AACR Annual Meeting in 2013
  • Inhibiting androgen receptor-associated Src signaling by VAL201 inhibits prostate cancer metastasis in an orthotopic mouse model with Valirx at AACR Annual Meeting in 2013
  • Improved imaging of orthotopic BxPC3 pancreatic adenocarcinoma xenograft using animal PET/CT at AACR Annual Meeting in 2013
  • Culturing Cancer Cells on Myoma Tissue: Development of a Novel Fully Human Organotypic 3D Invasion Model Applicable as a Preclinical Tool for Cancer Drug Development at AACR Annual Meeting in 2013

2012

  • Radium-223 Chloride Completely Prevents Tumor Growth in Bone and Increases Survival in a Mouse Model of Breast Cancer Bone Metastases in Preventive and Micro-metastatic Settings with Bayer HealthCare at AACR Annual Meeting in 2012
  • A Novel Organotypic 3D Invasion Platform to Advance Anti-Cancer Drug Development with University of Oulu (Institute of Dentistry) in 2012

2011

  • Alpharadin inhibits osteoclast differentiation in vitro and progression of established breast cancer bone metastases in vivo with Bayer HealthCare at AACR Annual Meeting in 2011
  • Cabozantinib (XL184), a Dual MET-VEGFR2 Inhibitor, Blocks Osteoblastic and Osteolytic Progression of Human Prostate Cancer Xenograft Tumors in Mouse Bone with Exelixis at EORTC Annual Meeting in 2011
  • Validation of In Vitro Assays for Identifying Compounds That Affect Breast and Prostate Cancer Cells at ASBMR Annual Meeting in 2011

2010

  • Diverging effects of doxorubicin, paclitaxel and cyclophosphamide on 4T1 mouse breast cancer primary tumor and metastases at Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference in 2010

2008

  • Quantitative image analysis method for measuring whole-body tumor burden in a mouse model of breast cancer bone metastasis at ASBMR Annual Meeting in 2008

2007

  • Heparin-like Polysaccharides Markedly Reduce Osteolytic Bone Destruction and Tumor Growth in a Mouse Model of Breast Cancer Bone Metastasis with BioTie Therapies and University of Virginia at ASBMR Annual Meeting in 2007